Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Captured microbes are then neutralized on engineered microbicidal surfaces
MRI is particularly valuable in pediatric care due to its non-invasive nature
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Growing patent filings and tier-2 innovators reflect expanding national research base
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Subscribe To Our Newsletter & Stay Updated
